22:44 , May 22, 2019 |  BC Extra  |  Clinical News

May 22 Clinical Quick Takes: Lilly's mirikizumab meets Crohn's endpoints; plus Novartis, 89bio and more

Lilly's mirikizumab meets in Phase II for Crohn’s  Mirikizumab (LY3074828) from Eli Lilly and Co. (NYSE:LLY) met the primary and secondary endpoints of improving clinical and endoscopic measures of disease activity at week 12 vs....
20:40 , Nov 1, 2018 |  BioCentury  |  Finance

OrbiMed’s NASH Terns

Terns Pharmaceuticals Inc. brings a dual U.S.-China strategy and a diverse pipeline to OrbiMed’s non-alcoholic steatohepatitis investment portfolio. OrbiMed co-led the biotech’s $80 million series B on Oct. 30 with fellow new investor Vivo Capital....
19:23 , Oct 26, 2018 |  BC Week In Review  |  Financial News

89Bio, a NASH start-up with Teva ties, debuts with $60M

89Bio Ltd. (San Francisco, Calif.) will use its $60 million series A financing to develop therapeutics for non-alcoholic steatohepatitis and other liver and metabolic diseases. The financing was co-led by OrbiMed Israel, OrbiMed US and...
22:52 , Oct 25, 2018 |  BC Extra  |  Financial News

89Bio, a NASH start-up with Teva ties, debuts with $60M

89Bio Ltd. (San Francisco, Calif.) will use its $60 million series A financing to develop therapeutics for non-alcoholic steatohepatitis and other liver and metabolic diseases. The financing was co-led by OrbiMed Israel, OrbiMed US and...